Other substances

Lumacaftor

An aromatic amide, a CFTR potentiator.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
2
 AI-suggested references
0
 Clinical trials

General information

Lumacaftor on PubChem

Marketed as

ORKAMBI (fixed-dose with Ivacaftor)

 

Structure image - Lumacaftor

CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O

Supporting references

Link Tested on Impact factor Notes Publication date
An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors
Spike protein Small molecule In silico 		in silico 4.00

Predicted to inhibit the SARS-CoV-2 spike protein via RBD binding.

 Aug/17/2020

AI-suggested references

Link Publication date
Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions
Mar/30/2021
Diabetes outbreak during COVID19 lock-down in a prediabetic patient with cystic fibrosis long treated with glargine.
Jun/02/2021
Export (.csv)